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ABSTRACT
Internal tandem duplication of the juxtamembrane domain of FMS-like tyrosine 
kinase 3 (FLT3-ITD) is the most prevalent genetic aberration present in 20-30% 
of acute myeloid leukaemia (AML) cases and is associated with a poor prognosis. 
FLT3-ITD expressing cells express elevated levels of NADPH oxidase 4 (NOX4)-
generated pro-survival hydrogen peroxide (H2O2) contributing to increased levels of 
DNA oxidation and double strand breaks. NOX4 is constitutively active and has been 
found to have various isoforms expressed at multiple locations within a cell. The 
purpose of this study was to investigate the expression, localisation and regulation 
of NOX4 28 kDa splice variant, NOX4D. NOX4D has previously been shown to localise 
to the nucleus and nucleolus in various cell types and is implicated in the generation 
of reactive oxygen species (ROS) and DNA damage. Here, we demonstrate that FLT3-
ITD expressing-AML patient samples as well as -cell lines express the NOX4D isoform 
resulting in elevated H2O2 levels compared to FLT3-WT expressing cells, as quantified 
by flow cytometry. Cell fractionation indicated that NOX4D is nuclear membrane-
localised in FLT3-ITD expressing cells. Treatment of MV4-11 cells with receptor 
trafficking inhibitors, tunicamycin and brefeldin A, resulted in deglycosylation of NOX4 
and NOX4D. Inhibition of the FLT3 receptor revealed that the FLT3-ITD oncogene 
is responsible for the production of NOX4D-generated H2O2 in AML. We found that 
inhibition of the PI3K/AKT and STAT5 pathways resulted in down-regulation of 
NOX4D-generated pro-survival ROS. Taken together these findings indicate that 
nuclear membrane-localised NOX4D-generated pro-survival H2O2 may be contributing 
to genetic instability in FLT3-ITD expressing AML.
INTRODUCTION
Aberrant signalling of receptor tyrosine kinases 
(RTKs) is associated with tumour development and 
transformation [1-3]. FMS-like tyrosine kinase 3 (FLT3) 
is a type III RTK expressed in approximately 90% of acute 
myeloid leukaemia (AML) and plays a critical role in 
normal haematopoiesis [4-6]. Internal tandem duplication 
(ITD) of sequences in the juxtamembrane domain is the 
most prevalent genetic aberration of FLT3, with a gain of 
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function mutation, implicated in 20-30% of AML patients 
[5, 7-10]. Patients with this mutation have a particularly 
poor prognosis with a high incidence of relapse [11-13]. 
Constitutive activation of the tyrosine kinase domain of 
FLT3-ITD results in autophosphorylation and activation 
of downstream pro-survival cascades including PI3K/
AKT, ERK1/2 and STAT5 resulting in the promotion of 
cell survival, proliferation and transformation in myeloid 
leukaemia [9, 10, 14-19]. It has been demonstrated that 
AML cells expressing the FLT3-ITD mutation produce 
higher levels of reactive oxygen species (ROS) and DNA 
damage compared to their wild-type counterpart [20-23].
ROS have been long implicated in leukaemia cancer 
pathology due to their ability to induce DNA damage 
[24, 25]. The NADPH oxidase (NOX) family consisting 
of NOX1-5 and dual oxidase (DUOX) 1 and 2, are well 
established producers of ROS [26], with NOX2 and 
NOX4 playing a central role in the increased production 
of hydrogen peroxide (H2O2) in AML [23, 27, 28]. 
NOX proteins vary in structure, subcellular localisation, 
biochemical characteristics and regulatory subunits 
(p22phox, p47phox, p67phox and Rac1/2). p22 phagocyte 
oxidase (p22phox) is a partner protein and is required for 
functionally active NOX1-4 [29-31]. Among the NOX 
family members NOX4 is unique. It is constitutively 
activated, generating H2O2, unlike its family members 
NOX1 and NOX2, which require an agonist for activation 
[32-34]. Oxidation of protein tyrosine phosphatases 
(PTPs) occurs in FLT3-ITD expressing AML cells. 
NOX4-driven ROS formation causes partial inactivation 
of DEP-1/PTPRJ, a transmembrane PTP responsible for 
negative regulation of FLT3 signalling, contributing to 
unfavourable downstream signalling [27].
NOX4 subcellular localisation plays an important 
role, given its constitutive activity. NOX4 has been 
reported to be expressed in the cytoskeleton [35], 
endoplasmic reticulum (ER) [30, 36-38], mitochondria 
[39, 40], plasma membrane [38, 41] and nucleus [42-44] 
in different cell types. Previous studies in our laboratory 
have shown that NOX4 and p22phox co-localise to the 
nuclear membrane by immunofluorescence in FLT3-
ITD expressing MV4-11 AML cell line contributing to 
DNA oxidation and double strand breaks (dsbs), possibly 
driving genetic instability [23].
Previous studies identified NOX4 isoforms, 
expressed at varying levels, in the presence of the prototype 
in the human lung cancer cell line, A549 cells. The truncated 
NOX4 splice variant D (28 kDa) lacks the majority of the 
transmembrane domain and has been shown to produce 
higher levels of ROS and DNA damage compared to its 
prototype [45]. NOX4D retains the NADPH and FAD-
binding domains required for electron transfer activity and 
ROS production despite its truncation [46]. NOX4D is 
localised to the nucleus and nucleolus in vascular smooth 
muscle cells (VSMC), A7R5 cells and in many other cells 
including human aortic vascular smooth muscle cells, 
human umbilical vein endothelium cells (HUVEC), H9C2 
rat cardiomyocytes, human embryonic kidney fibroblasts 
(HEK), mouse primary cardiac fibroblasts and rat neonatal 
cardiomyocytes. NOX4D is expected to be soluble rather 
than membrane-localised [42].
To investigate if FLT3-ITD expressing AML cells 
express NOX4D and in order to identify the localisation of 
NOX4D we utilised subcellular fractionation, inhibitors of 
FLT3-ITD and pro-survival signalling pathways, siRNA, 
alongside ROS specific probes and antibodies. Experiments 
were carried out in de novo primary AML samples, human 
patient-derived AML cell line MV4-11 and in the murine 
haematopoietic 32D cell lines stably harbouring FLT3-wild 
type (FLT3-WT) receptor and FLT3-ITD mutation.
We show that FLT3-ITD expressing AML patient 
samples and cell lines express the NOX4D 28 kDa splice 
variant. FLT3-ITD expressing AML cells express NOX4D 
in the nuclear membrane, which may be contributing 
to genetic instability in AML. NOX4D expression is 
dependent on the FLT3-ITD mutation. NOX4 partner 
protein p22phox does not regulate NOX4 or NOX4D protein 
expression. Inhibition of the PI3K and STAT5 pro-survival 
pathways results in decreased expression of NOX4D 
alongside a decrease in endogenous H2O2 detected using 
the H2O2 specific probe Peroxy Orange 1 (PO1). Inhibition 
of ERK1/2 signalling had no effect on NOX4D protein 
expression, however a decrease in p22phox protein levels 
alongside a decrease in endogenous H2O2 was observed. 
Inhibition of GSK3β resulted in increased expression 
of NOX4 and NOX4D, however, a slight decrease in 
endogenous H2O2 was observed. This demonstrates 
that NOX4D is downstream of FLT3-ITD signalling in 
AML, located in the nuclear membrane where it may be 
contributing to DNA damage and disease progression.
RESULTS
FLT3-ITD expressing AML patient samples, 
MV4-11 and 32D/FLT3-ITD cells express the 
NOX4 splice variant NOX4D 28 kDa in the 
nuclear membrane
FLT3-ITD expressing AML cells have been shown 
previously to express higher levels of total endogenous 
H2O2, DNA oxidation and dsbs compared to FLT3-WT 
cells [8, 23]. NOX4 has been well established as a producer 
of pro-survival ROS in FLT3-ITD expressing AML, 
contributing to DNA damage and disease progression [23, 
27]. As mentioned previously, NOX4 is unique to other 
members of the NOX family of proteins in its constitutive 
activation. Therefore, NOX4 subcellular localisation 
plays an important role in cellular regulation. Our group 
has previously shown that NOX4 and p22phox co-localise 
to the nuclear membrane in MV4-11 cells [23]. Previous 
studies identified the presence of NOX4 isoforms, 
including NOX4 splice variant NOX4D (28 kDa), to be 
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expressed and localised to the nucleus and nucleolus of 
VSMC where it is contributing to ROS production, DNA 
damage and genetic instability [42]. We investigated 
if FLT3-ITD- and FLT3-WT-expressing AML patient 
samples expressed the NOX4D isoform and also examined 
the expression and localisation of NOX4D 28 kDa in 
two cell lines: FLT3-ITD-expressing AML MV4-11 cell 
line and 32D cell line stably transfected with FLT3-WT 
or FLT3-ITD. Localisation of NOX4D was assessed by 
means of subcellular fractionation. We show that NOX4D 
is expressed in FLT3-ITD expressing patient samples and 
cells, but is absent in FLT3-WT patient samples and 32D 
cells transfected with the FLT3-WT receptor (Figure 1A-
1C). NOX4D is localised to the membrane and soluble 
nuclear fractions of MV4-11 cells (Figure 1B) and the 
membrane, soluble nuclear and chromatin bound nuclear 
(chr.b.nuclear) fractions of 32D cells stably transfected with 
FLT3-ITD (Figure 1C). In support of previous work, we 
have identified the NOX4 prototype (67 kDa) in the soluble 
nuclear fraction and p22phox in the membrane and soluble 
nuclear fractions in both MV4-11 cells (Figure 1B) and 
32D/FLT3-ITD cells (Figure 1C). Interestingly, we found 
NOX4 67 kDa was lacking from the membrane fraction in 
MV4-11 cells (Figure 1B). In contrast NOX4 67 kDa was 
observed in the membrane fraction of 32D/FLT3-ITD cells 
(Figure 1C). There are therefore clear differences in NOX4 
67 kDa subcellular localisation between these cell lines.
Specificity of NOX4 antibodies
Studies have raised issues with NOX4 antibody 
specificity in the past, due to difficulties in detecting 
NOX4 protein expression. Therefore, a key issue 
concerned the use of the Abcam NOX4 antibody 
(Ab109225) and the Novus Biologicals NOX4 antibody 
(NB110-58849) in our study. For this reason, a series of 
control experiments were first performed to validate the 
NOX4 antibodies employed in this study.
To validate the specificity of the Abcam NOX4 
antibody (Ab109225) against NOX4 67 kDa and NOX4D 
28 kDa in primary AML samples in this study, NOX4 
knockdowns were carried out in 32D/FLT3-ITD cells. 
Specific NOX4 knockdowns using NOX4 targeted siRNA 
and shRNA in 32D/FLT3-ITD cells resulted in depletion of 
NOX4 67 kDa protein levels detected using Abcam NOX4 
antibody (Supplementary Figure 1A). The remainder of the 
experiments in this study employed the Novus Biologicals 
NOX4 antibody (NB110-58849). In order to demonstrate 
specificity of this antibody for NOX4 67 kDa and NOX4D 
28 kDa, HEK-293-T cells were transfected with empty 
vector (EV)-HA or p-CMV3-C-HA encoding NOX4 and 
were analysed 48 h post transfection by western blot. NOX4 
overexpression in HEK 293-T cells resulted in increased 
NOX4 67 kDa and NOX4D 28 kDa protein expression in 
the presence of HA protein expression at the corresponding 
molecular weights compared to HEK 293-T cells transfected 
with EV (Supplementary Figure 1B). Together, these 
experiments validated that the NOX4 antibodies used in this 
study were specific for NOX4 67 kDa and NOX4D 28 kDa.
32D cells stably transfected with FLT3-ITD 
express higher levels of endogenous H2O2 
compared to FLT3-WT
FLT3-ITD expressing AML cells have been shown 
to produce elevated levels of ROS and DNA damage 
compared to their wild type counterpart [23]. Having 
confirmed that FLT3-ITD expressing AML patient 
samples and 32D cells express NOX4D whereas FLT3-
WT expressing patient samples and 32D cells do not, 
we investigated the effect of NOX4D expression on 
total endogenous H2O2. We demonstrate that 32D cells 
stably transfected with FLT3-ITD produced ~170% more 
endogenous H2O2 than 32D cells stably transfected with 
FLT3-WT receptor, as assessed with a H2O2 specific 
probe-PO1 (Figure 1D).
p22phox knockdown had no effect on NOX4 67 
kDa and NOX4D 28 kDa protein levels
p22phox is a partner protein and is required for 
functionally active NOX1-4 [30]. Specific p22phox 
knockdown allowed us to investigate the effects of p22phox 
on NOX4 67 kDa and NOX4D 28 kDa protein expression. 
Knockdown of p22phox had no effect on NOX4 67 kDa and 
NOX4D 28 kDa protein levels (Figure 2A).
Inhibition of glycosylation in MV4-11 cell line 
resulted in NOX4 67 kDa and NOX4D 28 kDa 
deglycosylation
Previous studies in our laboratory have found NOX4 
67 kDa to be glycosylated in FLT3-ITD expressing AML 
MV4-11 cells [28]. We investigated if NOX4D 28 kDa is 
glycosylated in the MV4-11 cell line. Cells were treated 
with glycosylation inhibitor, tunicamycin and receptor 
trafficking inhibitor, brefeldin A. Treatment of MV4-11 
cells with glycosylation and receptor trafficking inhibitors 
resulted in deglycosylation of NOX4D 28 kDa as seen by 
the presence of a lower molecular weight band marked by 
asterisks (Figure 2B).
Inhibition of FLT3-ITD in MV4-11 cell line and 
32D cells transfected with FLT3-ITD causes 
a decrease in NOX4 67 kDa and NOX4D 28 
kDa protein levels as well as reductions in total 
endogenous H2O2
32D cells transfected with FLT3-ITD and FLT3-
WT receptor along with MV4-11 cells were treated with 
FLT3-ITD inhibitor, PKC412. The inhibition of FLT3 
receptor resulted in a decrease in total endogenous H2O2 
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in 32D/FLT3-ITD cells, but not in 32D/FLT3-WT cells. 
As shown previously in Figure 1D 32D/FLT3-ITD cells 
possess ~170% more total endogenous H2O2 compared 
to their wild-type counterpart. Moreover, inhibition of 
Figure 1: FLT3-ITD expressing AML patient samples and cell lines express the NOX4D 28 kDa isoform. (A) Western 
blot analysis of NOX4 67 kDa and NOX4D 28 kDa protein expression in FLT3-ITD- and FLT-WT-expressing AML patient samples. 
β-actin and Vinculin were used as loading controls. (B and C) Subcellular fractionation was carried out in FLT3-ITD expressing AML cell 
line, MV4-11 (B) and 32D cells transfected with FLT3-WT or FLT3-ITD (C). Expression of NOX4 67 kDa, NOX4D 28 kDa and p22phox 
was assessed by means of western blot analysis. Equal loading of samples and verification of the subcellular fractions were demonstrated 
by probing for nuclear-localised NUP98, HDAC1 and Histone H3, membrane-localised calreticulin and KDEL and cytosolic-localised 
GAPDH. Blots are representative of five independent experiments. (D) (i) 32D cells stably transfected with FLT3-WT and FLT3-ITD were 
IL-3 starved overnight, followed by ROS visualisation with H2O2 specific probe, Peroxy Orange 1 (PO1) for 1 h before flow cytometric 
analysis. (ii) Bar chart shows relative mean PO1 fluorescence of 32D/FLT3-ITD cells expressed as a % of 32D/FLT3-WT cells. The results 
are representative of three independent experiments. Asterisks indicate statistically significant differences (****p<0.0001) as analysed by 
Student’s t-test. Error bars represent SD.
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FLT3 resulted in ~40% decrease in total endogenous 
H2O2 following treatment with 50 nM and 200 nM 
PKC412 specifically in 32D cells expressing the FLT3-
ITD mutation and not in cells expressing FLT3-WT 
receptor (Figure 3A). FLT3-ITD expressing MV4-11 
cells were treated with PKC412. Inhibition of the FLT3 
receptor in MV4-11 cells resulted in decreased NOX4 
67 kDa and NOX4D 28 kDa protein levels in whole cell 
lysates (Figure 3B) and reduced total endogenous H2O2. 
50 nM and 200 nM PKC412 treatments resulted in a 
decrease of 45-50% in total endogenous H2O2 (Figure 
3C). The inhibition of FLT3-ITD using AC220, another 
commonly used and very selective FLT3 receptor 
inhibitor, resulted in decreased NOX4D 28 kDa protein 
levels in the nuclear fractions of MV4-11 cells (Figure 
3D) and 32D/FLT3-ITD cells (Figure 3E). In Figure 
3D and 3E, Lamin A/C is used as a marker for nuclear 
fractions. Lamin A/C is cleaved by caspase-6 and serves 
as a marker of caspase-6 activation. During apoptosis, 
Lamin A/C is specifically cleaved to a large (40-45 
kDa) and a small (28 kDa) fragment. The cleavage of 
Lamin A/C results in nuclear dysregulation and death. 
These results suggest that both FLT3-ITD and NOX4D 
proteins play a role in the generation of H2O2 in MV4-
11 and 32D/FLT3-ITD cells and that FLT3-ITD activity 
is presumably an upstream regulator of NOX4D-
generated pro-survival ROS.
PI3K/AKT pathway is required for FLT3-ITD 
mediated-NOX4 67 kDa and -NOX4D 28 kDa 
generation of pro-survival H2O2
Constitutively activated FLT3-ITD kinase stimulates 
aberrant proliferative signalling through downstream 
signalling pathways including PI3K/AKT, ERK1/2, 
STAT5 and GSK3β. We have shown previously that 
NOX4- and p22phox-generated pro-survival ROS require 
AKT activation in MV4-11 cells [28]. Therefore, we 
examined the effect of PI3K/AKT inhibition on NOX4D 
28 kDa protein expression in membrane and soluble 
nuclear fractions of MV4-11 cells. Inhibition of AKT 
(Figure 4A) using PI3K inhibitor LY294002 resulted in 
slight decreases in NOX4 67 kDa protein expression and 
more noticeable decreases in NOX4D 28 kDa and p22phox 
protein expression in the soluble nuclear fraction (Figure 
4B). As shown, NOX4D 28 kDa protein expression is 
weak in the membrane fraction and it is therefore difficult 
to detect any change. We next examined the effect of 
AKT inhibition on the generation of total endogenous 
H2O2. AKT inhibition resulted in ~25% decrease in total 
endogenous H2O2 following treatment with 20 μM and 30 
μM LY294002 and ~35% decrease following treatment 
with 50 μM LY294002 (Figure 4C). Thus, activation of 
the AKT pathway is required for FLT3-ITD to produce 
NOX4D-generated ROS.
Figure 2: Knockdown of p22phox in FLT3-ITD expressing MV4-11 cells had no effect on NOX4 67 kDa and NOX4D 28 
kDa protein expression. NOX4D 28 kDa is glycosylated in FLT3-ITD expressing AML. (A) Western blot analysis of p22phox, NOX4 
67 kDa and NOX4D 28 kDa protein levels in MV4-11 whole cell lysates at 24 h following p22phox siRNA transfection. β-actin was used 
as a loading control. (B) Western blot analysis of NOX4 67 kDa and NOX4D 28 kDa protein expression in whole cell lysates following 
treatment with tunicamycin (5 μg/ml) (i) and brefeldin A (10 μg/ml) (ii) overnight. (Asterisks indicate a shift in protein molecular weight). 
β-actin and total protein were used as loading controls. Blots are representative of three independent experiments.
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NOX4 67 kDa- and NOX4D 28 kDa-generated 
pro-survival ROS are independent of ERK1/2 
signalling however p22phox-mediated H2O2 
production requires ERK1/2 activation
The ERK1/2 pathway is known to be activated 
downstream of constitutively activated FLT3-ITD. We 
investigated the effect of ERK1/2 signalling inhibition 
using U0126 in MV4-11 cells (Figure 5A) on NOX4D 28 
kDa protein expression. Inhibition of ERK1/2 signalling 
did not cause a decrease in NOX4 67 kDa and NOX4D 
28 kDa protein expression when compared to control, 
however, p22phox protein expression decreased following 
treatment with 50 μM and 100 μM U0126 (Figure 5B). 
Figure 3: Inhibition of the FLT3 receptor in 32D/FLT3-ITD cells and FLT3-ITD expressing MV4-11 cells reduces 
NOX4 67 kDa and NOX4D 28 kDa protein expression and total endogenous H2O2. Inhibition of the FLT3 receptor following 
treatment with PKC412, results in a decrease in total endogenous H2O2 in 32D/FLT3-ITD cells but not in 32D/FLT3-WT cells. (A) 32D/
FLT3-WT and 32D/FLT3-ITD cells were IL-3 starved overnight and treated for 24 h with PKC412 (50 nM and 200 nM), followed by 
staining with H2O2 specific probe PO1 for 1 h before FACS reading. Bar charts show relative mean PO1 fluorescence of treated cells 
expressed as % of control. The results are representative of four independent experiments. Asterisks indicate statistically significant 
differences (****p<0.0001) as analysed by Student’s t-test. Error bars represent SD. (B) Western blot analysis of NOX4 67 kDa and NOX4D 
28 kDa protein expression in MV4-11 whole cell lysates following treatment with PKC412 for 24 h at indicated concentrations. β-actin 
was used as a loading control. Blots are representative of three independent experiments. (C) (i) Flow cytometric analysis of mean relative 
PO1 fluorescence in MV4-11 cells treated with PKC412 for 24 h at indicated concentrations. (ii) Bar chart shows relative mean PO1 
fluorescence of treated cells expressed as % of control. Results are representative of three independent experiments. Asterisks indicate 
statistically significant differences (****p<0.0001) as analysed by Student’s t-test. Error bars represent SD. (D and E) Western blot analysis 
of NOX4D 28 kDa protein expression in the nuclear fraction following treatment with AC220 (10 nM, 20 nM and 30 nM) for 12 h in MV4-
11 cells (D) and 32D cells transfected with FLT3-ITD (E). Equal loading of nuclear fractions was demonstrated by probing for nuclear-
localised Lamin A/C. Blots are representative of three independent experiments.
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This suggests that NOX4 67 kDa- and NOX4D 28 kDa-
generated pro-survival ROS are independent of ERK1/2 
signalling. A decrease of 40-45% in total endogenous H2O2 
was observed following treatment with 50 μM and 100 
μM U0126 (Figure 5C).
NOX4 67 kDa and NOX4D 28 kDa generate pro-
survival ROS downstream of STAT5 signalling
Previous studies have shown that FLT3-ITD 
drives evident activation of STAT5 signalling compared 
Figure 4: NOX4 67 kDa- and NOX4D 28 kDa–generated pro-survival ROS require AKT activation. (A) Western blot 
analysis of AKT signalling in FLT3-ITD expressing MV4-11 cells following treatment with LY294002 (20 μM, 30 μM and 50 μM) for 16 
h. β-actin and total protein were used as loading controls. (B) NOX4 67 kDa, NOX4D 28 kDa and p22phox protein expression in membrane 
and soluble nuclear fractions of MV4-11 cells following treatment with LY294002 for 16 h at indicated concentrations. Equal loading 
of samples is shown by total protein and verification of subcellular fractions were assessed by probing for nuclear-localised NUP98 and 
membrane-localised calreticulin. Western blot analysis is representative of three independent experiments. (C) (i) Flow cytometric analysis 
of mean relative PO1 fluorescence in MV4-11 cells treated with LY294002 for 16 h at indicated concentrations. (ii) Bar chart shows relative 
mean PO1 fluorescence of treated cells expressed as % of control. Results are representative of three independent experiments. Asterisks 
indicate statistically significant differences (****p<0.0001) as analysed by Student’s t-test. Error bars are representative of SD.
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to FLT3-WT resulting in increased mRNA and protein 
expression of NOX4 [27, 47, 48]. Given that treatment 
with pimozide clearly reduced NOX4 mRNA in FLT3-
ITD expressing MV4-11 cells [27], we investigated 
the effect of STAT5 inhibition in MV4-11 cells (Figure 
6A) on NOX4D 28 kDa protein expression. Treatment 
Figure 5: NOX4 67 kDa- and NOX4D 28 kDa-generated pro-survival ROS are independent of ERK1/2 signalling. 
p22phox generated H2O2 requires ERK1/2 activation. (A) Western blot analysis of ERK1/2 signalling in FLT3-ITD expressing MV4-
11 cells following treatment with U0126 (10 μM, 20 μM, 50 μM and 100 μM) for 16 h. α-tubulin and total protein were used as loading 
controls. (B) NOX4 67 kDa, NOX4D 28 kDa and p22phox protein expression in membrane and soluble nuclear fractions of MV4-11 cells 
following treatment with U0126 for 16 h at indicated concentrations. Equal loading of samples is shown by total protein and verification 
of subcellular fractions was assessed by probing for nuclear-localised NUP98 and membrane-localised calreticulin. Western blot analysis 
is representative of three independent experiments. (C) (i) Flow cytometric analysis of mean relative PO1 fluorescence in MV4-11 cells 
treated with U0126 for 16 h at indicated concentrations. (ii) Bar chart shows relative mean PO1 fluorescence of treated cells expressed as 
% of control. Results are representative of four independent experiments. Asterisks indicate statistically significant differences (*p<0.05, 
***p<0.001, **** p<0.0001) as analysed by Student’s t-test. Error bars are representative of SD.
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with indicated concentrations of pimozide resulted in a 
pronounced decrease in NOX4 67 kDa, NOX4D 28 kDa 
and p22phox protein expression following treatment with 
20 μM pimozide (Figure 6B). Furthermore, inhibition of 
STAT5 signalling caused a decrease of 30-40% in total 
endogenous H2O2 at all concentrations (Figure 6C), 
indicating a role for STAT5 signalling in the production of 
NOX4D-generated pro-survival ROS.
Figure 6: NOX4 67 kDa and NOX4D 28 kDa generate H2O2 downstream of STAT5 activation. (A)Western blot analysis of 
STAT5 signalling in FLT3-ITD expressing MV4-11 cells following treatment with pimozide (5 μM, 10 μM and 20 μM) for 16 h. β-actin 
and total protein were used as loading controls. (B) NOX4 67 kDa, NOX4D 28 kDa and p22phox protein expression in membrane and 
soluble nuclear fractions of MV4-11 cells following treatment with pimozide for 16 h at indicated concentrations. Equal loading of samples 
is shown by total protein and verification of subcellular fractions were assessed by probing for nuclear-localised NUP98 and membrane-
localised calreticulin. Western blot analysis is representative of four independent experiments. (C)(i) Flow cytometric analysis of mean 
relative PO1 fluorescence in MV4-11 cells treated with pimozide for 16 h at indicated concentrations. (ii) Bar chart shows relative mean 
PO1 fluorescence of treated cells expressed as % of control. Results are representative of three independent experiments. Asterisks indicate 
statistically significant differences (****p<0.0001) as analysed by Student’s t-test. Error bars are representative of SD.
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Inhibition of GSK3β signalling in MV4-11 cell 
line increases NOX4 67 kDa and NOX4D 28 kDa 
protein levels and decreases p22phox protein levels
Previous studies in our laboratory have 
demonstrated that PKC412-mediated p22phox down-
regulation requires GSK3β activation, establishing a role 
for GSK3β signalling in post-translational regulation of 
NOX4 partner protein p22phox [22]. SB216763, a drug 
described as an inhibitor of GSK3β [49, 50] was found 
to decrease pGSK3β (Ser 9) protein levels significantly 
in MV4-11 cells, therefore resulting in the activation of 
GSK3β signalling (Figure 7A). Treatment of MV4-11 
cells with indicated concentrations of SB216763 showed 
no obvious effect on NOX4 67 kDa, NOX4D 28 kDa and 
p22phox protein levels in membrane and soluble nuclear 
fractions (Figure 7B). However, activation of GSK3β 
signalling increased total endogenous H2O2 by 45-50% 
following treatment with 1 μM and 2 μM SB216763 and 
~40% following treatment with 5 μM SB216763 (Figure 
7C). Lithium chloride (LiCl) is widely used as a GSK3β 
inhibitor [51]. Inhibition of GSK3β using LiCl caused an 
increase in pGSK3β (Ser 9) protein levels (Figure 7D) 
in MV4-11 cells, indicative of inhibition of the pathway. 
This increase coincided with an increase in NOX4 67 kDa 
and NOX4D 28 kDa proteins in membrane and soluble 
nuclear fractions. Interestingly, p22phox protein levels 
decreased following treatment with 50 mM LiCl in both 
membrane and soluble nuclear fractions (Figure 7E). 
Inhibition of GSK3β activation had little or no effect on 
total endogenous H2O2 levels (Figure 7F).
DISCUSSION
FLT3-ITD is the most prevalent mutation in AML 
accounting for 20-30% of patient cases [5, 7, 8] and has 
been associated with an aggressive phenotype [11-13]. 
NOX-derived ROS have been shown to have numerous 
roles in leukaemia including cell survival, cell proliferation 
and a differentiation block [52, 53]. Leukaemic oncogenes 
have been widely documented in the regulation of NOX 
proteins and their partner protein p22phox [8, 54]. Our 
group has shown that 32D cells transfected with FLT3-
ITD possess higher NOX4 and p22phox levels than their 
wild type counterpart contributing to genomic instability 
in FLT3-ITD expressing AML. Furthermore, 32D/FLT3-
ITD cells exhibit higher levels of total endogenous and 
nuclear H2O2 and DNA damage than 32D/FLT3-WT cells 
[23].
Unlike other NOX family members, NOX4 is 
constitutively activated. Subcellular localisation of 
NOX4 is key to its role in ROS production and genetic 
instability. NOX4 has been reported to be expressed in 
the nucleus [55-62] amongst other previously identified 
locations including the cytoskeleton [35], ER [30, 36-
38], mitochondria [39, 40] and plasma membrane [38, 
41]. Our laboratory has previously shown that NOX4 
and p22phox co-localise to the nuclear membrane of FLT3-
ITD expressing MV4-11 cells [23]. Previous studies 
have identified the presence of NOX4 isoforms or splice 
variants [45]. NOX4D 28 kDa is of particular interest, as it 
is found in the nucleus and nucleolus of multiple cell types 
including human aortic smooth muscle cells, HUVECs, 
H9C2 rat cardiomyocyte cells, HEK cells, mouse primary 
cardiac fibroblasts and rat neonatal cardiomyocytes where 
it contributes to ROS production and DNA damage [42].
In this study, we investigated the expression, 
localisation and regulation of NOX4D-generated pro-
survival ROS in FLT3-ITD expressing AML. We found 
that FLT3-ITD expressing AML patient samples and cells 
possess the NOX4D splice variant. FLT3-ITD expressing 
AML cells express NOX4D in the membrane and soluble 
nuclear fractions. NOX4D was not detected in the FLT3-
WT expressing patient samples and cells, suggesting a role 
for nuclear membrane-localised NOX4D 28 kDa in the 
generation of pro-survival ROS in FLT3-ITD expressing 
AML. In line with previous work, we detected NOX4 67 
kDa in the soluble nuclear fraction and its partner protein 
p22phox in the membrane and soluble nuclear fractions of 
MV4-11 and 32D/FLT3-ITD cells (Figure 1). 32D cells 
stably transfected with FLT3-ITD express NOX4D 28 
kDa and possess elevated levels of total endogenous H2O2 
compared to their wild-type counterpart. Importantly, to 
our knowledge, this is the first study to identify the role 
of nuclear membrane-localised NOX4D 28 kDa in pro-
survival ROS production and genomic instability in FLT3-
ITD expressing AML cells (Figure 1).
p22phox is a partner protein of NOX1-4 and is required 
for NOX4 activation [30]. We found that p22phox knockdown 
had no significant effect on NOX4 67 kDa and NOX4D 28 
kDa protein levels (Figure 2). Interestingly, previous studies 
have shown that NOX4 knockdown resulted in depletion of 
p22phox protein levels in HUVECs with no change in p22phox 
mRNA expression [43]. This suggests that the formation of 
NOX4 and p22phox complex in the nucleus of HUVECs is 
responsible for the stabilisation of p22phox at the protein level.
Recent studies in our laboratory have revealed that 
NOX4 67 kDa is glycosylated in FLT3-ITD expressing 
MV4-11 cells [28]. We show that NOX4D 28 kDa is also 
glycosylated in MV4-11 cells, by using a glycosylation 
inhibitor, tunicamycin, and a receptor trafficking inhibitor, 
brefeldin A. By inhibiting glycosylation, NOX4D 28 kDa 
was observed at a lower molecular weight (Figure 2). 
Indeed, NOX4D 28 kDa is glycosylated in A549 cells 
[45]. We have shown that deglycosylation of NOX4 67 
kDa [28] and now NOX4D 28 kDa (Figure 2) coincides 
with significant decreases in total endogenous H2O2 [28]. 
This suggests that the glycosylation of NOX4 67 kDa 
and NOX4D 28 kDa may be important for their role in 
the production of pro-survival ROS and DNA damage 
in AML. Tunicamycin and brefeldin A have recently 
been shown to inhibit receptor trafficking of the FLT3-
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Figure 7: Inhibition of GSK3β signalling results in elevated NOX4 67 kDa and NOX4D 28 kDa protein expression. (A) 
Western blot analysis of GSK3β signalling in FLT3-ITD expressing MV4-11 cells following treatment with SB216763 (1 μM, 2 μM and 5 
μM) for 16 h. β-actin and total protein were used as loading controls. (B) NOX4 67 kDa, NOX4D 28 kDa and p22phox protein expression in 
membrane and soluble nuclear fractions of MV4-11 cells following treatment with SB216763 for 16 h at indicated concentrations. Equal 
loading of samples is shown by total protein and verification of subcellular fractions were assessed by probing for nuclear-localised NUP98 
and membrane-localised calreticulin. Western blot analysis is representative of four independent experiments. (C)(i) Flow cytometric 
analysis of mean relative PO1 fluorescence in MV4-11 cells treated with SB216763 for 16 h at indicated concentrations. (ii) Bar chart shows 
relative mean PO1 fluorescence of treated cells expressed as % of control. Results are representative of three independent experiments. 
Asterisks indicate statistically significant differences (***p<0.001, ****p<0.0001) as analysed by Student’s t-test. Error bars are representative 
of SD. (D) Western blot analysis of GSK3β signalling in FLT3-ITD expressing MV4-11 cells following treatment with lithium chloride 
(10 mM, 20 mM and 50 mM) for 16 h. β-actin and total protein were used as loading controls. (E) NOX4 67 kDa, NOX4D 28 kDa and 
p22phox protein expression in membrane and soluble nuclear fractions of MV4-11 cells following treatment with lithium chloride for 16 h 
at indicated concentrations. Equal loading of samples is shown by total protein and verification of subcellular fractions were assessed by 
probing for nuclear-localised NUP98 and membrane-localised calreticulin. Western blot analysis is representative of three independent 
experiments. (F)(i) Flow cytometric analysis of mean relative PO1 fluorescence in MV4-11 cells treated with lithium chloride for 16 h 
at indicated concentrations. (ii) Bar chart shows relative mean PO1 fluorescence of treated cells expressed as % of control. Results are 
representative of four independent experiments. Asterisks indicate statistically significant differences (**p<0.01, ***p<0.001) as analysed by 
Student’s t-test. Error bars are representative of SD.
Oncotarget105451www.impactjournals.com/oncotarget
ITD receptor to the plasma membrane which caused 
inactivation of both the AKT and ERK1/2 pathways [16, 
28]. Although tunicamycin and brefeldin A inhibit many 
glycosylated proteins, mild inhibition of glycosylation 
using tunicamycin in combination with FLT3 kinase 
inhibitors has shown therapeutic potential for the treatment 
of FLT3-ITD expressing AML [63].
We have previously demonstrated that FLT3-ITD is 
involved in the up-regulation of NOX4 both at mRNA and 
protein levels [23, 27]. Inhibition of FLT3-ITD activity 
using several FLT3 receptor inhibitors including AC220, 
AG1295 and PKC412 caused a decrease in NOX4 mRNA 
and protein expression [27, 28] presenting a role for FLT3-
ITD in NOX4-generated ROS production in AML. Here, 
we have shown that FLT3-ITD patient samples and cells 
express the NOX4D 28 kDa splice variant alongside a 
dramatic increase in total endogenous H2O2 compared to 
their wild-type counterpart that do not express NOX4D 
(Figure 1). Inhibition of the FLT3 receptor using PKC412 
caused a decrease in total endogenous H2O2 in 32D/
FLT3-ITD cells compared to 32D/FLT3-WT cells (Figure 
3). FLT3-ITD inhibition in MV4-11 cells treated with 
PKC412 resulted in down-regulation of NOX4 67 kDa and 
NOX4D 28 kDa protein expression alongside a decrease 
in H2O2 levels (Figure 3). Treatment of MV4-11 and 32D/
FLT3-ITD cells with FLT3 receptor inhibitor AC220 also 
led to decreased expression of NOX4D 28 kDa. PKC412 
(midostaurin) has recently been approved by the FDA 
and AC220 is currently being tested in clinical trials 
for the treatment of AML [64-66]. Previous studies has 
shown that FLT3-ITD inhibition using PKC412 and NOX 
inhibition via diphenyleneiodonium (DPI) in 32D/FLT3-
ITD cells resulted in ~25-40% decrease in γH2AX levels, 
a marker of dsbs [23]. Together these findings suggest that 
the FLT3-ITD oncogene is responsible for the regulation 
and production of nuclear membrane-localised NOX4D-
generated H2O2 in AML contributing to genetic instability 
and an aggressive phenotype.
Figure 8: A schematic of the proposed mechanism of FLT3-ITD-driven NOX4D-generated H2O2 in AML. GSK3β, 
ERK1/2, PI3K/AKT and STAT5 pro-survival pathways are located downstream of FLT3-ITD. Activation of AKT and STAT5 signalling 
by the FLT3-ITD oncogene results in the activation and production of DNA damaging NOX4D-generated H2O2 at the nuclear membrane.
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Three major pro-survival pathways are activated 
downstream of FLT3-ITD in AML: PI3K/AKT, ERK1/2 
and STAT5 pathway [10, 16]. We have shown that the 
PI3K/AKT pathway needs to be activated in order for 
NOX4 to generate its oncogenic effects in AML [27, 
28]. Inhibition of the PI3K/AKT pathway revealed that 
the PI3K/AKT pathway is responsible for the activation 
and generation of NOX4-, NOX4D- and p22phox generated 
H2O2 (Figure 4). Although the ERK1/2 pathway is located 
downstream of FLT3-ITD, inhibition of ERK1/2 signalling 
was found to have no noticeable effects on NOX4- and 
NOX4D- protein expression. However, inactivation of 
ERK1/2 signalling revealed that ERK1/2 activation is 
involved in the stimulation and production of p22phox-
mediated H2O2 production in AML (Figure 5). p22
phox is 
a partner protein of NOX1, NOX2 and NOX3 as well as 
NOX4, all of which have a role in ROS production. We 
have previously demonstrated that NOX2 is also involved 
in ROS production and DNA damage contributing to 
genetic instability in FLT3-ITD expressing AML. This 
same study confirmed that NOX1 does not contribute 
significantly to ROS production or dsbs [23]. Patient 
derived FLT3-expressing myeloid cells have been shown 
to express NOX2, NOX4 and NOX5. However, their 
murine counterpart have been shown to express NOX1, 
NOX2 and NOX4. These cells did not express NOX3 [53]. 
Therefore it is likely that ERK1/2 activation is involved 
in the production of NOX2-generated H2O2 in FLT3-ITD 
expressing AML. Recent findings have identified STAT5 
signalling downstream of FLT3-ITD and its requirement 
for the up-regulation of NOX4-generated H2O2, alongside 
the inactivation of DEP-1 PTP a negative regulator 
of FLT3 signalling activity [27]. Inhibition of STAT5 
signalling revealed that activated STAT5 is required for 
the production of NOX4-, NOX4D- and p22phox-generated 
ROS (Figure 6). This suggests that NOX4D may also have 
a role in the partial inactivation of DEP-1 PTP resulting 
in cellular transformation in FLT3-ITD expressing AML.
GSK3β is another pathway known to be located 
downstream of FLT3-ITD. Inhibition of the PI3K/AKT 
pathway in MV4-11 cells resulted in increased expression 
of pGSK3β (Ser 9) suggesting that the GSK3β pathway is 
not located downstream of the PI3K/AKT pathway [28]. 
Phosphorylation of GSK3β at Serine 9 decreased following 
ERK1/2 inhibition suggesting that the GSK3β pathway is 
located downstream of ERK1/2 (data not shown). Inhibition 
of FLT3-ITD signalling caused a decrease in phosphorylation 
of GSK3β (Ser 9), resulting in increased GSK3β activation 
which has been shown previously to play a crucial role in the 
post-translational regulation of p22phox [22, 28]. SB216763 
is described as an inhibitor of GSK3β, and GSK3β is 
inhibited when it is phosphorylated. In disagreement with 
this, SB216763 was found to decrease levels of pGSK3β in 
MV4-11 cells (Figure 7), suggesting that it is acting as an 
activator of GSK3β. It is possible that SB216763 could have 
different effects in other cell types. However, based on our 
findings, we advise careful consideration and assessment of 
pGSK3β levels when using this drug. Activation of GSK3β 
was found to have no noticeable effect on NOX4-, NOX4D- 
and p22phox protein expression, however an increase in H2O2 
levels was observed (Figure 7). The activation of GSK3β 
signalling has been found to be pro-apoptotic in several 
systems and can provoke mitochondrial injury and this 
may be responsible for the increase in H2O2 levels [67-69]. 
Lithium chloride, also described as an inhibitor of GSK3β, 
resulted in the expected increase in pGSK3β in MV4-11 
cells, indicating inhibition (Figure 7). Inhibition of GSK3β 
signalling using LiCl revealed an increase in NOX4- and 
NOX4D-protein expression, however, p22phox protein levels 
decreased. Moreover, inhibition of GSK3β signalling had 
little or no effect on total endogenous H2O2 (Figure 7).
In conclusion, we suggest that the FLT3-ITD oncogene 
is responsible for the activation and generation of NOX4D-
generated pro-survival H2O2 at the nuclear membrane 
contributing to DNA damage and genetic instability in AML. 
Glycosylation of NOX4 and NOX4D is essential for the 
production of pro-survival ROS. Activation of PI3K/AKT 
and STAT5 signalling is required in order for NOX4D to 
generate its oncogenic effects. These findings are summarised 
in Figure 8. This study emphasises the potential of NOX as 
an effective therapeutic target in FLT3-ITD expressing AML, 
as inhibition and deglycosylation of NOX4 and NOX4D can 
decrease the levels of H2O2 and DNA damage that would 
otherwise contribute to genetic instability. From a clinical 
point of view, adaptation of tumour cells to enhanced ROS 
production may result in tumour cells being less responsive to 
the standard cytotoxic chemotherapy, which operates through 
severe oxidative stress. Together the data presented here and 
in previous studies by our laboratories identifies receptor 
trafficking inhibitors/glycosylation inhibitors and NOX 
inhibitors as potential therapies for the treatment of FLT3-
ITD expressing AML which when treated in combination 
with standard chemotherapy may improve the effectiveness 
of the treatment.
MATERIALS AND METHODS
Primary AML patient samples
Blood samples from newly diagnosed untreated 
de novo AML patients were obtained in accordance with 
the Declaration of Helsinki and with approval of the 
institutional review board of the University Hospital Jena, 
Germany. Mononuclear cells were purified as previously 
described in [21]. FLT3 mutational analysis was done by 
standard PCR methods to group the patients into FLT3-
WT or FLT3-ITD.
Cell culture and treatments
The human leukaemic cell line MV4-11 
(homozygous for the FLT3-ITD mutation) was purchased 
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from DSMZ (Braunschweig, Germany). The 32D cell 
lines, stably transfected with FLT3-WT and FLT3-ITD 
[18], were a kind gift from Prof. Hubert Serve (Goethe 
University Frankfurt, Germany). MV4-11 and 32D cells 
were maintained in RPMI-1640 medium supplemented 
with 10% FBS, 2 mM L-glutamine and 1% penicillin/
streptomycin in a humidified incubator at 37°C with 5% 
CO2. For the 32D cell lines, 10% WEHI-conditioned 
medium was added as a source of IL-3. HEK 293-T 
cells were maintained in Dulbecco’s Modified Eagle’s 
Medium (DMEM), supplemented with 10% FBS, 10 
mM L-glutamine and 1% penicillin/streptomycin in a 
humidified incubator at 37°C with 5% CO2.
FLT3-ITD was inhibited using PKC412 (50 nM, 
200 nM and 250 nM; Tocris) for up to 24 h and AC220 
(10nM, 20nM, and 30nM; generous gift of Dr. Siavosh 
Mahboobi (University of Regensburg, Germany)) for 12 
h. Glycosylation was inhibited using tunicamycin (5 μg/
ml; Sigma) and brefeldin A (10 μg/ml; Sigma) overnight. 
Inhibition of PI3K/AKT was achieved via treatment with 
LY294002 (20 μM, 30 μM and 50 μM; Cell Signaling) for 
16 h; inhibition of ERK1/2 via U0126 (10 μM, 20 μM, 50 
μM and 100 μM; Sigma) for 16 h; inhibition of STAT5 
via pimozide (5 μM, 10 μM and 20 μM; Merck Millipore) 
for 16 h; modulation of GSK3β via SB216763 (1 μM, 2 
μM and 5 μM; Tocris); inhibition of GSK3β via Lithium 
chloride (LiCl) (10 mM, 20 mM and 50 mM; Sigma) 
for 16 h. Vehicle controls used were dimethylsulfoxide 
(DMSO; for all drugs unless otherwise stated), sterile 
water (for LiCl) and Ethanol (for brefeldin A).
Antibodies
Primary antibodies used for immunoblotting 
included NOX4 (Ab109225; Abcam; used for human 
primary AML samples), NOX4 (NB110-58849; 
Novus Biologicals; used for all other analyses), p22phox 
(#SC20781; Santa Cruz Biotechnology), β-Actin (A5441), 
α-Tubulin (T5168) (Sigma), Vinculin (BZL03106; Biozol), 
NUP98 (Ab179911 (13C1)), Histone H3 (Ab1220), 
Calreticulin (Ab22683), KDEL (Ab12223) (Abcam), 
GAPDH (#5174), Lamin A/C (#2032), HDAC1 (#5356), 
pAKT (Ser473; #9271), AKT(#9272), pERK1/2 (Thr202/
Tyr204; #9106), ERK1/2 (#4696), pGSK3β (Ser9; #9336), 
GSK3β (#9315) (Cell Signaling), pSTAT5 (Tyr694/699; 
#04-886; Millipore), STAT5 (#610191; BD Biosciences) 
and HA (#MMS-101R; Cambridge Bioscience).
Western blotting
The immunoblotting procedure was carried out 
as previously described [22]. Briefly, whole cells were 
lysed in radio-immunoprecipitation assay (RIPA) buffer 
[Tris–HCl (50mM; pH 7.4), 1% NP-40, 0.25% sodium 
deoxycholate, NaCl (150mM), EGTA (1mM), sodium 
orthovanadate (1mM), sodium fluoride (1mM), cocktail 
protease inhibitors (Roche, Welwyn, Hertforshire, UK) 
and phenylmethanesulfonyl fluoride (1mM)] for 35-45 
minutes at 4°C in a vortex, followed by centrifugation at 
14,000 rpm for 15 min to remove cell debris. Subcellular 
fractionation was performed to detect the expression and 
localisation of the NOX4 28kDa isoform (NOX4D) using a 
subcellular fractionation kit (Thermo Scientific, Waltham, 
MA USA), according to the manufacturer’s instructions. 
The protein concentration was determined using the Bio-
Rad Protein Assay (Bio-Rad, Hemel Hempstead, UK). 
In all cases equivalent amounts of protein, were resolved 
using SDS-PAGE in 4X Protein Sample Loading Buffer 
(LI-COR, cat# P/N 928-40004) followed by transfer 
to nitrocellulose membrane (Schleicher and Schuell, 
Whatman, Dassel, Germany). Total protein levels were 
analysed using REVERT total protein stain (LI-COR, cat# 
P/N 926-11011) as per manufacturer’s instructions and 
imaged on a LI-COR Odyssey infrared imaging system 
(LI-COR Biosciences UK Ltd, Cambridge, UK). The 
membranes were blocked for 1 h and incubated overnight 
with primary antibodies. The membranes were incubated 
in secondary antibody coupled with Alexa Fluor 680 
or 800. Antibody reactive bands were detected using a 
LI-COR Odyssey infrared imaging system.
Small interfering RNA (siRNA) and small 
hairpin RNA (shRNA)
siRNA transfection of MV4-11 cells was performed 
using the Nucleofector kit L (Amaxa, Cologne, Germany) 
and Amaxa Nucleofector Technology (Q-001 program) 
according to the company’s protocol. The predesigned 
siRNA used for p22phox siRNA was A: s201230. The 
sequences are available from the manufacturer’s website. 
For the negative control, the siRNA used was Silencer 
Select Negative Control #1 siRNA. All were purchased 
from Ambion, Warrington, UK. NOX4 siRNA and shRNA 
in 32D/FLT3-ITD cells were carried out as previously 
decribed [27].
Measurement of intracellular H2O2
Measurement of intracellular H2O2 was performed as 
previously described in [28]. Briefly, following treatments, 
total intracellular H2O2 was measured by incubating cells 
with 5 μM of cell-permeable H2O2-probe PO1 (Tocris) for 
1 h at 37°C in the dark. Cells were quantified by flow 
cytometry using FACSCalibur (BD Biosciences, Europe) 
and Cellquest Pro software (Becton Dickinson). The mean 
fluorescent intensity of 10,000 events was determined.
NOX4 overexpression transfections
For NOX4 overexpression in HEK 293-T cells, cells 
were transfected using Calcium Phosphate. Briefly, cells 
were seeded 5 h prior to transfection to allow confluency 
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of 70%. 4 μg of pCMV3-C-HA encoding NOX4 
(#HG15189-CY; Sino Biological, UK) was added to 
CaCl2. The DNA/CaCl2 mixture was then added dropwise 
to 2X HBSS at a ratio of 1:1. Samples were allowed to 
stand for 1-2 min after which the solution was distributed 
to the pre-seeded cells in a dropwise manner. Cells were 
then incubated overnight to allow the transfection to 
proceed, after which cells were reseeded for experimental 
purposes and lysed 48 h later.
Statistical analysis
The results are expressed as a percentage of 
control, set to 100%. Values are representative of mean 
± SD and are representative of three or more independent 
experiments. Statistical significance was analyzed by 
Student’s t-test (GraphPad Prism 6 software) with p<0.05 
representing a significant result.
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